# Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis

> **NCT02565576** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 44 (actual)

## Conditions studied

- Myasthenia Gravis, Generalized

## Interventions

- **DRUG:** Placebo
- **DRUG:** CFZ533

## Key facts

- **NCT ID:** NCT02565576
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-29
- **Primary completion:** 2017-07-31
- **Final completion:** 2017-12-19
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2021-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02565576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02565576, "Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02565576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*